Trial · NCT01006603
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Proportion of Patients Reaching HbA1c <7% After 52 Weeks of Treatment Without Confirmed or Severe Hypoglycaemia. | Saxagliptin 5 mg | All patients | 37.9 | percentage of participants | |
| Proportion of Patients Reaching HbA1c <7% After 52 Weeks of Treatment Without Confirmed or Severe Hypoglycaemia. | Glimepiride 1 - 6 mg | All patients | 38.2 | percentage of participants | |
| Proportion of Patients Reaching HbA1c <7% After 52 Weeks of Treatment Without Confirmed or Severe Hypoglycaemia. | Saxagliptin 5 mg | patients aged <75 years (n=217, n=216) | 39.2 | percentage of participants | |
| Proportion of Patients Reaching HbA1c <7% After 52 Weeks of Treatment Without Confirmed or Severe Hypoglycaemia. | Glimepiride 1 - 6 mg | patients aged <75 years (n=217, n=216) | 33.3 | percentage of participants | |
| Proportion of Patients Reaching HbA1c <7% After 52 Weeks of Treatment Without Confirmed or Severe Hypoglycaemia. | Saxagliptin 5 mg | patients aged ≥75 years (n=142, n=143) | 35.9 | percentage of participants | |
| Proportion of Patients Reaching HbA1c <7% After 52 Weeks of Treatment Without Confirmed or Severe Hypoglycaemia. | Glimepiride 1 - 6 mg | patients aged ≥75 years (n=142, n=143) | 45.5 | percentage of participants | |
| Proportion of Patients Having Experienced at Least One Hypoglycaemic Event (Confirmed or Severe) Over the 52-week Double-blind Treatment Period. | Saxagliptin 5 mg | 1.1 | percentage of patients | ||
| Proportion of Patients Having Experienced at Least One Hypoglycaemic Event (Confirmed or Severe) Over the 52-week Double-blind Treatment Period. | Glimepiride 1 - 6 mg | 15.3 | percentage of patients | ||
| Change From Baseline to Week 52 in HbA1c. | Saxagliptin 5 mg | -0.44 | 95% Confidence Interval -0.51 to -0.37 | % of glycosylated hemoglobin | |
| Change From Baseline to Week 52 in HbA1c. | Glimepiride 1 - 6 mg | -0.64 | 95% Confidence Interval -0.71 to -0.57 | % of glycosylated hemoglobin | |
| Proportion of Patients Achieving a Therapeutic Glycaemic Response at Week 52 Defined as HbA1c <7.0% | Saxagliptin 5 mg | 44.7 | percentage of responders | ||
| Proportion of Patients Achieving a Therapeutic Glycaemic Response at Week 52 Defined as HbA1c <7.0% | Glimepiride 1 - 6 mg | 54.7 | percentage of responders | ||
| Change From Baseline to Week 52 in Fasting Plasma Glucose (FPG) | Saxagliptin 5 mg | -0.73 | 95% Confidence Interval -0.89 to -0.57 | mmol/L | |
| Change From Baseline to Week 52 in Fasting Plasma Glucose (FPG) | Glimepiride 1 - 6 mg | -1.29 | 95% Confidence Interval -1.45 to -1.13 | mmol/L | |
| Change From Baseline to Week 52 in Insulin | Saxagliptin 5 mg | -2.0 | 95% Confidence Interval -3.1 to -1.0 | µU/mL | |
| Change From Baseline to Week 52 in Insulin | Glimepiride 1 - 6 mg | -0.6 | 95% Confidence Interval -1.6 to 0.5 | µU/mL | |
| Change From Baseline to Week 52 in β-cell Function (as Measured by Homeostasis Model Assessment-β [HOMA-β] | Saxagliptin 5 mg | 3.83 | 95% Confidence Interval 0.79 to 6.88 | percentage of change from baseline | |
| Change From Baseline to Week 52 in β-cell Function (as Measured by Homeostasis Model Assessment-β [HOMA-β] | Glimepiride 1 - 6 mg | 16.22 | 95% Confidence Interval 13.23 to 19.20 | percentage of change from baseline |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01006603/results